Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound bleeding and trauma hemostasis. The company also provides traditional Chinese medicines, chemical medicines, active pharmaceutical ingredients, and pharmaceutical intermediates. In addition, it engages in elderly care services, rehabilitation therapy, psychological counseling, and end-of-life care; hospital management; technical services; and healthcare investment activities. The company was incorporated in 1998 and is headquartered in Nanjing, China.